Comparative Pharmacology
Head-to-head clinical analysis: ESTRACE versus SAFYRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRACE versus SAFYRAL.
ESTRACE vs SAFYRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol, a form of estrogen, binds to and activates nuclear estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent physiological effects including development of secondary sexual characteristics, regulation of reproductive cycle, and effects on bone density, lipid metabolism, and cardiovascular system.
Safyral is a combination of ethinyl estradiol and drospirenone. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, preventing ovulation. Drospirenone is a progestin with anti-mineralocorticoid activity, which may reduce fluid retention, and anti-androgenic activity, which may improve acne. It also increases cervical mucus viscosity, impeding sperm penetration.
1 to 2 mg orally once daily for continuous estrogen replacement; 0.1% cream applied vaginally 1 to 2 times daily for atrophic vaginitis.
One tablet (drospirenone 3 mg/ethinyl estradiol 0.03 mg) orally once daily for 24 days, followed by 4 days of placebo.
None Documented
None Documented
Terminal half-life: 13-27 hours (mean 19 hours); clinical context: supports once-daily dosing for hormone replacement.
16.3 hours (range 12-21 hours) for drospirenone; 32.5 hours (range 24-42 hours) for ethinyl estradiol (EE); clinical context: steady-state achieved after 10 days for drospirenone, 7 days for EE
Renal: 50-80% as glucuronide and sulfate conjugates; fecal: 10-20%; biliary: minor (<5%).
Urine (40% as metabolites, 20% unchanged; fecal 30% as metabolites; biliary excretion contributes to enterohepatic circulation, prolonging elimination)
Category C
Category C
Estrogen
Oral Contraceptive Progestin/Estrogen